AKLI Stock Overview
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Akili, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$1.67 |
| 52 Week Low | US$0.19 |
| Beta | 1.99 |
| 1 Month Change | 62.53% |
| 3 Month Change | 70.17% |
| 1 Year Change | -72.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.03% |
Recent News & Updates
Shareholder Returns
| AKLI | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 63.9% | 1.3% | 0.7% |
| 1Y | -72.7% | -6.6% | 23.9% |
Return vs Industry: AKLI underperformed the US Healthcare Services industry which returned -6.6% over the past year.
Return vs Market: AKLI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| AKLI volatility | |
|---|---|
| AKLI Average Weekly Movement | 39.0% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKLI's share price has been volatile over the past 3 months.
Volatility Over Time: AKLI's weekly volatility has increased from 22% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 68 | Matt Franklin | www.akiliinteractive.com |
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization.
Akili, Inc. Fundamentals Summary
| AKLI fundamental statistics | |
|---|---|
| Market cap | US$31.56m |
| Earnings (TTM) | -US$59.49m |
| Revenue (TTM) | US$1.68m |
18.8x
P/S Ratio-0.5x
P/E RatioIs AKLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKLI income statement (TTM) | |
|---|---|
| Revenue | US$1.68m |
| Cost of Revenue | US$819.00k |
| Gross Profit | US$859.00k |
| Other Expenses | US$60.35m |
| Earnings | -US$59.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 51.19% |
| Net Profit Margin | -3,545.47% |
| Debt/Equity Ratio | 22.2% |
How did AKLI perform over the long term?
See historical performance and comparison